They showed that Compound 44 inhibited the activities of both isolated Trx and TrxR at a low micromolar level and that this effect was accounting for its preferential cytotoxicity against cancer cells, Trx and TrxR inhibition being more marked in breast cancer cells than in mammary epithelial cells. The gene discussed is TXN; the disease is breast carcinoma.